Lipitor, Atorvastatin

Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 1,063 in Lipitor, Atorvastatin (generic)

  1. New cures and treatments could cause pricey headachesRead the original story w/Photo

    Mar 18, 2015 | Washington Examiner

    Breakthrough drugs for lowering cholesterol and fighting cancer are expected to hit the market over the next few years, saving lives but also leaving the federal government struggling to pay for high-cost drugs without restricting access or resorting to innovation-killing price caps. Drug pricing has received renewed attention lately as public and private health plans struggle to pay for two expensive new hepatitis treatments that carry $1,000-per-pill price tags.

    Comment?

  2. Dr. Roach: The great vitamin debateRead the original story w/Photo

    Mar 18, 2015 | Lubbock Avalanche-Journal

    Answer : I do not. In my opinion, a healthy diet makes a deficiency of a vitamin or mineral severe enough to weaken the immune system unlikely.

    Comment?

  3. Statin Use in Early Pregnancy Might Be SafeRead the original story

    Mar 17, 2015 | Journal Watch

    Statin use during the first trimester of pregnancy is not associated with increased risk for congenital malformations, according to an observational study in the BMJ . Statins currently are contraindicated in pregnancy because of concerns about possible teratogenic effects.

    Comment?

  4. Esperion Drug Shows Promise in Cutting Cholesterol LevelsRead the original story

    Mar 17, 2015 | The Washington Post

    Adding the lowest dose of the drug known as ETC-1002 to treatment with statin drugs like Pfizer Inc.'s Lipitor cut bad LDL cholesterol by 17 percent more than statins alone, the Plymouth, Michigan-based company said in a statement. A higher dose increased the effect, cutting cholesterol by 24 percent.

    Comment?

  5. This New Drug Can Lower Your Cholesterol and Prevent Heart Against DiseasesRead the original story w/Photo

    Mar 17, 2015 | International Business Times

    A recent study has revealed that adding a new biological drug to the existing class of drugs that helps lower cholesterol level may further improve the results, in addition to lowering the risk of heart diseases, including stroke and attack. According to the research conducted by a group of doctors, the patients who were administered the new class of biological drug were twice less likely to suffer from a cardiac disease as compared to those who were given the conventional treatment, which uses statin drugs such as Lipitor or Zocor.

    Comment?

  6. Now Available: Indoco Remedies Limited (INDOCO) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Mar 17, 2015 | PR-inside.com

    Indoco Remedies Limited is a pharmaceutical company. The company manufactures and markets formulations and active pharmaceutical ingredients.

    Comment?

  7. Esperion Therapeutics Announces Positive Top-Line Phase 2b Results...Read the original story

    Mar 16, 2015 | BioSpace

    Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002 Added To Stable Statin Therapy In Patients With Hypercholesterolemia ETC-1002-009 Study Meets Primary Endpoint LDL-Cholesterol Lowering Significantly Greater Than Placebo ETC-1002 Observed to Be Safe and Well-Tolerate Conference Call and Webcast on Tuesday, March 17, 2015 at 8:00 a.m. Eastern Time ANN ARBOR, MI -- -- 03/17/15 -- Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 compared with placebo in patients with hypercholesterolemia on stable statin therapy.

    Comment?

  8. Some Foods and Supplements Can Interfere with Heart MedicinesRead the original story

    Mar 17, 2015 | Health News Digest

    Be careful about eating grapefruit if you are one of the many Americans taking a statin drug to lower your cholesterol, nutrition experts at UT Southwestern Medical Center warn. Grapefruit contains chemicals called furanocoumarins that interfere with an enzyme involved in metabolizing many of the statin drugs, including atorvastatin, lovastatin, and simvastatin.

    Comment?

  9. Experimental Drugs Cut Heart RiskRead the original story w/Photo

    Mar 17, 2015 | The San Diego Union-Tribune

    Drugmakers developing a new generation of cholesterol treatments surged Monday after releasing data that showed the injections cut the rate of major cardiac events and death as they slashed bad cholesterol. Repatha, made by Amgen, and Praluent, under development by Sanofi and Regeneron, both cut LDL, or bad, cholesterol levels by more than 60 percent in studies published Sunday in the New England Journal of Medicine.

    Comment?

  10. Studies Boost Hopes for New Class of Cholesterol MedicinesRead the original story

    Mar 15, 2015 | ABC News

    New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.

    Comment?

  11. STTG Market Recap Mar 16, 2015Read the original story w/Photo

    Mar 16, 2015 | Trader Mike

    The market continues its inverse relationship with the U.S. dollar. As the dollar fell Monday, the market rallied.

    Comment?

  12. Porton Fine Chem buys fellow China intermediates firm DongbangRead the original story w/Photo

    Mar 16, 2015 | In-PharmaTechnologist.com

    Porton Fine Chemicals will buy fellow China-based firm Jiangxi Dongbang Pharmaceutical adding intermediates for antivirals and cholesterol busters to its portfolio. The Chongqing-headquartered firm will pay $41.5m - $16m in cash and the rest in stock - for Dongbang, funding the takeover through a recent private placement through which it raised $11m.

    Comment?

  13. Studies boost hopes for new class of cholesterol-lowering drugsRead the original story w/Photo

    Mar 16, 2015 | CBC News

    Statins are among the most widely prescribed drugs in Canada and the U.S. Amgen Canada Inc. says about 70 per cent of patients were on a statin at the start of the extension studies into its new generation cholesterol-lower medicine evolocumab. New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems.

    Comment?

  14. Studies boost hopes for new cholesterol medicines; hints of side effects need more researchRead the original story w/Photo

    Mar 16, 2015 | Canada.com

    New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.

    Comment?

  15. Health Exchange: Amgen, other drug company shares jump on cholesterol drug findingsRead the original story w/Photo

    Mar 16, 2015 | MarketWatch

    A new class of cholesterol drugs that showed potential over the weekend to combat a number of diseases drove up the prices of three major biopharmaceutical companies on Monday and drove two of them to record highs. shares all moved higher.

    Comment?

  16. A New Class Of Experimental Cholesterol Drugs Are Outperforming Traditional StatinsRead the original story w/Photo

    Mar 16, 2015 | Switched

    New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.

    Comment?

  17. New type of drug could be cholesterol breakthroughRead the original story w/Photo

    Mar 16, 2015 | CBS News

    New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks , death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.

    Comment?

  18. NeoStem's One-Year Trial Results Could Bounce SharesRead the original story w/Photo

    Mar 12, 2015 | Seeking Alpha

    With shares trading near their lows after the "disappointing results" from the interim data, they could skyrocket higher if NeoStem makes the data clearer for investors to understand. NeoStem is a biotechnology company, specializing in stem cell treatments.

    Comment?

  19. Dr. Roizen: What's Good for Your Heart But Bad for Your Blood?Read the original story w/Photo

    Mar 12, 2015 | WSYR-AM Syracuse

    Dr. Mike Roizen says "The risk of diabetes increased along with the amount of drug used mainly for atorvastatin, the generic form of Pfizer's Lipitor, and simvastatin. The U.S. Food and Drug Administration said in 2012 that Lipitor and Crestor would carry warnings about an increase in blood-sugar levels in patients, leading to a greater risk of diabetes."

    Comment?

  20. Renal effects of atorvastatin and rosuvastatin in patients with...Read the original story

    Mar 12, 2015 | CiteULike

    Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease : a randomised clinical trial. The role of lipid-lowering treatments in renoprotection for patients with diabetes is debated.

    Comment?